Human papillomavirus vaccination 2020 guideline update: American Cancer Society guideline adaptation.
Adolescent
Adult
Advisory Committees
/ standards
Alphapapillomavirus
/ immunology
American Cancer Society
/ organization & administration
Child
Clinical Competence
Female
Health Personnel
/ education
Health Plan Implementation
/ organization & administration
Humans
Immunization Schedule
Intersectoral Collaboration
Mass Vaccination
/ organization & administration
Middle Aged
Neoplasms
/ pathology
Papillomavirus Infections
/ pathology
Papillomavirus Vaccines
/ administration & dosage
United States
Vaccination Coverage
/ organization & administration
Young Adult
cancer prevention
human papillomavirus (HPV)
immunization
vaccine
Journal
CA: a cancer journal for clinicians
ISSN: 1542-4863
Titre abrégé: CA Cancer J Clin
Pays: United States
ID NLM: 0370647
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
06
05
2020
accepted:
19
05
2020
pubmed:
9
7
2020
medline:
17
12
2020
entrez:
9
7
2020
Statut:
ppublish
Résumé
The American Cancer Society (ACS) presents an adaptation of the current Advisory Committee on Immunization Practices recommendations for human papillomavirus (HPV) vaccination. The ACS recommends routine HPV vaccination between ages 9 and 12 years to achieve higher on-time vaccination rates, which will lead to increased numbers of cancers prevented. Health care providers are encouraged to start offering the HPV vaccine series at age 9 or 10 years. Catch-up HPV vaccination is recommended for all persons through age 26 years who are not adequately vaccinated. Providers should inform individuals aged 22 to 26 years who have not been previously vaccinated or who have not completed the series that vaccination at older ages is less effective in lowering cancer risk. Catch-up HPV vaccination is not recommended for adults aged older than 26 years. The ACS does not endorse the 2019 Advisory Committee on Immunization Practices recommendation for shared clinical decision making for some adults aged 27 through 45 years who are not adequately vaccinated because of the low effectiveness and low cancer prevention potential of vaccination in this age group, the burden of decision making on patients and clinicians, and the lack of sufficient guidance on the selection of individuals who might benefit.
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
274-280Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 American Cancer Society.
Références
Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M. Human papillomavirus-attributable cancers-United States, 2012-2016. MMWR Morb Mortal Wkly Rep. 2019;68:724-728.
Saslow D, Castle PE, Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28.
Saslow D, Andrews KS, Manassaram-Baptiste D, et al. Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement. CA Cancer J Clin. 2016;66:375-385.
Bruni L, Diaz M, Barrionuevo-Rosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4:e453-e463.
Brotherton JM, Winch KL, Bicknell L, Chappell G, Saville M. HPV vaccine coverage is increasing in Australia. Med J Aust. 2017;206:262.
Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68:718-723.
Fisher-Borne M, Preiss AJ, Black M, Roberts K, Saslow D. Early outcomes of a multilevel human papillomavirus vaccination pilot intervention in federally qualified health centers. Acad Pediatr. 2018;18(2 suppl):S79-S84.
Mitchell K, Saraiya M, Bhatt A. Increasing HPV vaccination rates through national provider partnerships. J Womens Health (Larchmt). 2019;28:747-751.
Saslow D, Sienko J, Nkonga JLZ, Brewer NT. Creating a national coalition to increase human papillomavirus vaccination coverage. Acad Pediatr. 2018;18(2 suppl):S11-S13.
Escoffery C, Riehman K, Watson L, et al. Facilitators and barriers to the implementation of the HPV VACs (Vaccinate Adolescents Against Cancers) Program: a consolidated framework for implementation research analysis. Prev Chronic Dis. 2019;16:E85.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1-24.
Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68:698-702.
American Society for Clinical Oncology (ASCO) Institute for Quality. ASCO Guidelines Methodology Manual. Accessed January 22, 2020. instituteforquality.org/guideline-development-process
Shah MA, Oliver TK, Peterson DE, et al. ASCO clinical practice guideline endorsements and adaptations. J Clin Oncol. 2020;38:834-840.
Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med. 2010;51:421-424.
Ahmed F, Temte JL, Campos-Outcalt D, Schunemann HJ. Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC). Vaccine. 2011;29:9171-9176.
Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705-1708.
Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.
Herweijer E, Sundstrom K, Ploner A, Uhnoo I, Sparen P, Arnheim-Dahlstrom L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: a population-based study. Int J Cancer. 2016;138:2867-2874.
Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:l1161.
Racey CS, Albert A, Donken R, et al. Cervical intraepithelial neoplasia rates in British Columbia women: a population-level data linkage evaluation of the school-based HPV immunization program. J Infect Dis. 2020;221:81-90.
Iversen OE, Miranda MJ, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women. JAMA. 2016;316:2411-2421.
Lazcano-Ponce E, Torres-Ibarra L, Cruz-Valdez A, et al. Persistence of immunity when using different human papillomavirus vaccination schedules and booster-dose effects 5 years after primary vaccination. J Infect Dis. 2019;219:41-49.
Kjaer SK, Nygard M, Dillner J, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 Nordic countries. Clin Infect Dis. 2018;66:339-345.
Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10:2147-2162.
Gilkey MB, McRee AL. Provider communication about HPV vaccination: a systematic review. Hum Vaccin Immunother. 2016;12:1454-1468.
Sturm L, Donahue K, Kasting M, Kulkarni A, Brewer NT, Zimet GD. Pediatrician-parent conversations about human papillomavirus vaccination: an analysis of audio recordings. J Adolesc Health. 2017;61:246-251.
Hopfer S, Wright ME, Pellman H, Wasserman R, Fiks AG. HPV vaccine recommendation profiles among a national network of pediatric practitioners: understanding contributors to parental vaccine hesitancy and acceptance. Hum Vaccin Immunother. 2019;15:1776-1783.
Kempe A, O’Leary ST, Markowitz LE, et al. HPV vaccine delivery practices by primary care physicians. Pediatrics. 2019;144:e2019475.
O’Leary ST, Nyquist AC. Why AAP recommends initiating HPV vaccination as early as age 9. Accessed January 30, 2020. aappublications.org/news/2019/10/04/hpv100419
Kimberlin DW, Brady MT, Jackson MA, Long SS, eds. Redbook: 2018 Report of the Committee on Infectious Diseases. 31st ed. American Academy of Pediatrics; 2018.
Goleman MJ, Dolce M, Morack J. Quality improvement initiative to improve human papillomavirus vaccine initiation at 9 years of age. Acad Pediatr. 2018;18:769-775.
St Sauver JL, Rutten LJF, Ebbert JO, Jacobson DJ, McGree ME, Jacobson RM. Younger age at initiation of the human papillomavirus (HPV) vaccination series is associated with higher rates of on-time completion. Prev Med. 2016;89:327-333.
Biancarelli DL, Drainoni ML, Perkins RB. Provider experience recommending HPV vaccination before age 11 years. J Pediatr. 2020;217:92-97.
Rodriguez AM, Zeybek B, Vaughn M, et al. Comparison of the long-term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: a database study. Cancer. 2020;126:1656-1667.
Chesson H. Overview of Health Economic Models for HPV Vaccination of Mid-Adults. Advisory Committee on Immunization Practices. Published 2019. Accessed January 30, 2020. cdc.gov/vaccines/acip/meetings/downloads/slides-2019-06/HPV-4-Chesson-508.pdf
Laprise JF, Chesson HW, Markowitz LE, et al. Effectiveness and cost-effectiveness of human papillomavirus vaccination through age 45 years in the United States. Ann Intern Med. 2020;172:22-29.
Brisson M, Laprise JF. Cost-Effectiveness of Extending HPV Vaccination Above Age 26 Years in the U.S. Meeting of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention; 2019.
Oshman LD, Davis AM. Human papillomavirus vaccination for adults: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). JAMA. 2020;323:468-469.
National Vaccine Advisory Committee. Overcoming barriers to low HPV vaccine uptake in the United States: recommendations from the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on June 9, 2015. Public Health Rep. 2016;131:17-25.
National Cancer Advisory Board. Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer. A Report to the President of the United States from the President's Cancer Panel. National Cancer Institute; 2014.
GAVI, The Vaccine Alliance. Report to the Board. Published 2019. Accessed June 2, 2020. gavi.org/sites/default/files/board/minutes/2019/2019-Mtg-1_03%20-%202016-2020%20Strategy_Progress%20challenges%20and%20risks.pdf
Kreimer AR, Cernuschi T, Rees H, Saslow D, Porras C, Schiller J. Prioritisation of the human papillomavirus vaccine in a time of constrained supply. Lancet Child Adolesc Health. 2020;4:349-351.
Ali H, Guy RJ, Wand H, et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis. 2013;13:140.
Drolet M, Benard E, Perez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394:497-509.
Wangu Z, Hsu KK. Impact of HPV vaccination on anogenital warts and respiratory papillomatosis. Hum Vaccin Immunother. 2016;12:1357-1362.
McClung NM, Gargano JW, Park IU, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women-United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019;68:337-343.
Guo F, Cofie LE, Berenson AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med. 2018;55:197-204.
Luostarinen T, Apter D, Dillner J, et al. Vaccination protects against invasive HPV-associated cancers. Int J Cancer. 2018;142:2186-2187.
World Health Organization. Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem. Accessed June 2, 2020. who.int/activities/a-global-strategy-for-elimination-of-cervical-cancer
American Cancer Society. Mission HPV Cancer Free. Accessed April 6, 2020. cancer.org/hpv